cyclosporine has been researched along with Non-alcoholic Fatty Liver Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bigi, L; Conti, A; Lasagni, C; Pellacani, G | 1 |
| Benet, M; Castell, JV; Donato, MT; García-Mediavilla, MV; Guzmán, C; Jover, R; Martínez-Chantar, ML; Pisonero-Vaquero, S; Sánchez-Campos, S | 1 |
| Dorn, C; Hellerbrand, C; Ledermann, M; Patsenker, E; Saegesser, H; Schneider, V; Stickel, F | 1 |
3 other study(ies) available for cyclosporine and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Therapy; Comorbidity; Cyclosporine; Etanercept; Female; Hepatitis B; Hepatitis C; Humans; Infliximab; Interleukin-17; Latent Tuberculosis; Male; Methotrexate; Middle Aged; Non-alcoholic Fatty Liver Disease; Psoriasis; Ustekinumab | 2018 |
Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease.
Topics: Animals; CCAAT-Enhancer-Binding Protein-alpha; Cells, Cultured; Cyclosporine; Doxycycline; Fatty Liver; Humans; Male; Mice; Mitogen-Activated Protein Kinase 1; Non-alcoholic Fatty Liver Disease; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Tetracycline; Thiazepines; Transcription, Genetic; Valproic Acid | 2015 |
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.
Topics: Animals; Bile Ducts; Calcineurin Inhibitors; Cyclosporine; Disease Progression; Everolimus; Fatty Liver; Immunosuppressive Agents; Ligation; Liver Cirrhosis, Experimental; Male; Matrix Metalloproteinases; Non-alcoholic Fatty Liver Disease; Portal Pressure; Rats; Rats, Wistar; RNA, Messenger; Sirolimus; Tacrolimus; TOR Serine-Threonine Kinases; Triglycerides | 2011 |